Skip to main content

Advertisement

SpringerLink
Log in

Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens.

Methods

Patients received capecitabine, 2,500 mg/m2/day PO for 14 days (D1–14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0).

Results

Forty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1–12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1–12.5%) and the disease control rate was 46.7% (95% CI, 28.6–87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6–16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3–39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%).

Conclusions

The combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1–9

    Article  PubMed  Google Scholar 

  2. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE (2005) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev:CD004064

  3. Wilson D, Hiller L, Geh JI (2005) Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 17:81–90

    CAS  Google Scholar 

  4. Peter WTP, David PK, Steven MP, Joel ET (2005) Cancer of the stomach. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 909–939

  5. Brugarolas A, Garcia-Moran M, Lacave AJ (1975) Chemotherapy in advanced gastric cancer: a controlled clinical study (abstract). Proc Am Assoc Cancer Res 16:169

    Google Scholar 

  6. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344–1347

    Article  PubMed  CAS  Google Scholar 

  7. Park YH, Ryoo BY, Choi SJ, Kim HT (2004) A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90:1329–1333

    Article  PubMed  CAS  Google Scholar 

  8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281

    Article  PubMed  CAS  Google Scholar 

  9. Stouch TR, Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315–328

    Article  PubMed  CAS  Google Scholar 

  10. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789–3798

    Article  PubMed  CAS  Google Scholar 

  11. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137–141

    Article  PubMed  Google Scholar 

  12. Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U (2006) Multidrug resistance in locally advanced breast cancer. Tumour Biol 27:309–318

    Article  PubMed  CAS  Google Scholar 

  13. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854–859

    Article  PubMed  CAS  Google Scholar 

  14. Miyamoto K, Yoshida S, Saito D, Shimada Y, Tajiri H, Yamaguchi H, Ohkura H, Yoshino M, Yoshida T, Okazaki N (1990) Pilot phase II study of cis-diamminedichloroplatinum (II) against metastatic gastric cancers. Jpn J Clin Oncol 20:169–176

    PubMed  CAS  Google Scholar 

  15. Lacave AJ, Izarzugaza I, Anton Aparicio LM, Valle Pereda M, Gracia Marco JM, Buesa JM (1983) Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 6:35–38

    Article  PubMed  CAS  Google Scholar 

  16. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307–310

    Article  PubMed  CAS  Google Scholar 

  17. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N, Cascinu S (2000) A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11:1263–1266

    Article  PubMed  CAS  Google Scholar 

  18. Shin SJ, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM (2004) The Efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-FU based chemotherapy: a single-center phase ii study. Cancer Res Treat 36:367–371

    Article  PubMed  Google Scholar 

  19. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 34:8–13

    Article  PubMed  Google Scholar 

  20. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323

    PubMed  CAS  Google Scholar 

  21. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N, Colucci G (2005) Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell’ Italia Meridionale (prot. 2106) Am J Clin Oncol 28:581–585

    Article  PubMed  CAS  Google Scholar 

  22. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 92:1850–1854

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Korea Science and Engineering Foundation (KOSEF) through the Cancer Metastasis Research Center (CMRC) at Yonsei University College of Medicine.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, Seoul, 120-752, South Korea

    Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh & Hyun Cheol Chung

Authors
  1. Sang Joon Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hei-Cheul Jeung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joong Bae Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hye Jin Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Byoung Chul Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sun Young Rha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nae Choon Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jae Kyung Roh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hyun Cheol Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyun Cheol Chung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shin, S.J., Jeung, HC., Ahn, J.B. et al. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol 61, 157–165 (2008). https://doi.org/10.1007/s00280-007-0470-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0470-3

Keywords

Search

Navigation